PRGN-3005
Precigen therapeutics
['ovarian', '$pgen']
precigen shares encouraging data from phase 1 study of prgn-3005 ultracar-t in ovarian cancer patients at 2023 asco annual meeting. $pgen #asco #ovariancancer #positive 
Real-time news analysis & sentiment scoring for the stocks in the Nasdaq100
Powered by @streetbeat_com of @SP500Tracker
Disclosure: https://t.co/ixCFGXlG3M